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Aims Bone morphogenetic proteins (BMPs) are involved in embryonic and adult blood vessel formation in health and
disease. Previous studies have shown that BMP endothelial cell precursor-derived regulator (BMPER) plays an
important role in endothelial cell function and blood vessel formation. BMPER is a key regulator of BMP4 activity
and a prerequisite for BMP pathway activation by BMP4 in endothelial cells. Here, we characterize the BMPER
promoter and elucidate mechanisms of BMPER regulation.
Methods
and results
To investigate transcriptional mechanisms of BMPER expression, the murine BMPER promoter was cloned and
characterized. A series of 50 deletions of the BMPER promoter revealed that the proximal promoter contains activat-
ing cis-elements. By overexpression or siRNA-based knockdown, we demonstrate that BMPER expression is activated
by Krüppel-like factor (KLF) 15. As determined by gelshift analyses, KLF15 binds directly to a predicted KLF-binding
element at 2284 bp within the BMPER promoter. Co-expression experiments show that Sp1 acts as an antagonist
for KLF15-induced promoter activation. Endothelin-1 was identified as a potent inhibitor of KLF15 and BMPER
expression in endothelial cells, suggesting that KLF15 is a transducer of endothelin-1 activity on BMPER expression.
The selective ETB endothelin receptor antagonist BQ788 abolished the downregulation of BMPER expression by
endothelin-1.
Conclusion Mechanistically, we found that KLF15 is a strong and direct activator of the BMPER expression. BMPER is downre-
gulated by endothelin-1 in a dose-dependent fashion and in parallel to KLF15. As KLF15 deficiency is accompanied by
a vascular phenotype and BMPER is necessary for proper blood vessel formation, we suggest a chain of events in
which the effects of endothelin-1 on BMPER are mediated by KLF15.
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1. Introduction
Bone morphogenetic proteins (BMPs) are members of the trans-
forming growth factor-b (TGF-b) superfamily. Originally, they
have been identified by their ability to induce ectopic bone for-
mation and have been extensively studied during embryonic devel-
opment, where they control axis formation and organogenesis.
A growing body of evidence suggests that they serve also as impor-
tant regulators in vascular development and disease.1 Important
insights came from the discovery of mutations of the BMP
receptors in patients with familial pulmonary artery hypertension
or teleangiectasia, both being clinically important vascular dis-
eases.2 BMP4 induces capillary sprouting of endothelial cells.3
Chronic infusion of BMP4 induces arterial hypertension and
leads to endothelial dysfunction in mice.4 BMP2 and 4 exert
pro-inflammatory effects on the endothelium.5– 7 Recent studies
suggest that BMPs are upregulated in athero-prone regions in
blood vessels and may contribute to vascular calcification and
the development of atherosclerotic plaques.8,9 Accordingly, loss
of BMP pathway activity by genetic deletion of BMP receptors or
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BMP-dependent transcription factors (the Smads) results in a
hypomorphic vascular phenotype during mouse embryogen-
esis.10– 12 As unequivocally demonstrated by these data, a fine-
tuned BMP activity is indeed necessary to maintain normal vascu-
lature, and BMP4 contributes to unfavourable conditions of the
vascular wall.
BMP endothelial cell precursor-derived regulator (BMPER) is a
novel extracellular BMP modulator that we have identified
earlier by its differential expression in embryonic endothelial cell
precursors.13 In mouse and zebrafish, BMPER is expressed at
sites and at the time of vasculogenesis consistent with a functional
role for BMPER in vascular events. Indeed, BMPER controls the
effect of BMP4 on critical endothelial cell functions such as sprout-
ing and migration.14 In accordance with this endothelial cell sprout-
ing and migration phenotype, lack of BMPER results in disarray of
intersomitic blood vessels in developing zebrafish.15 Time course
observations show that BMPER expression during mouse and
zebrafish development is temporally and spatially controlled.13,15,16
Studies of the spatial expression of BMPER in relation to BMPs
and other BMP modulators such as chordin suggest that
BMPER expression is at least in part complementary to BMP4
expression.17 Taken together, BMPER is a key modulator of BMP
signalling particularly in blood vessel formation, and its expression
is tightly regulated.
Until now, the regulation of BMP activity has been studied at
several levels including (i) protein–protein interactions of BMPs
with extracellular modulators, (ii) BMP ligand binding to cell
surface receptors, and (iii) intracellular signal transduction path-
ways. BMPs are transported within the extracellular space and
thereby form concentration gradients. This process is modulated
by the presence of extracellular BMP-binding proteins, such as
chordin, which assist to transport BMPs over longer distances by
protecting them from degradation. Thereby, chordin may contrib-
ute to the accumulation of BMPs at sites remote from their original
site of expression and thus may also increase BMP activity at these
sites. On the other hand, chordin is a direct BMP antagonist by
interfering with BMP–BMP receptor interaction. In contrast,
BMPER is not diffusible, and thus helps to accumulate BMP activity
at the site of BMPER expression. In this scenario, the control of
BMPER expression would be essential to regulate the local BMP
activity and would reflect an additional level of BMP regulation.
2. Methods
2.1 Antibodies and reagents
Monoclonal anti-human BMPER antibody was purchased from R&D
Systems (MAB1956); monoclonal anti-FLAG M2 antibody, recombi-
nant endothelin-1 (E-7764), and selective ETB endothelin receptor
antagonist BQ788 (B157) were purchased from Sigma-Aldrich.
2.2 Cell culture
Human umbilical vein endothelial cells (HUVECs) and bovine aortic
endothelial cells (BAECs) were cultured in endothelial cell growth
medium (Provitro) with 10% foetal bovine serum (FBS). C166 cells
are mouse yolk sac-derived embryonic endothelial cells and were cul-
tured as COS7 in DMEM (GIBCO) with 10% FBS.18 Cultures were
kept at 378C in a 5% CO2-humidified atmosphere. This project was
approved by the local ethics committee of the University of Freiburg
(208/04) and conforms with the principles outlined in the Declaration
of Helsinki.
2.3 Promoter constructs
The 50 flanking region of the BMPER gene was cloned by PCR using
genomic DNA from C57/BL6 mice as template. A series of 50
deleted fragments were cloned into promoterless pGL3-basic vector
(Promega). A mutation of the Krüppel-like factor (KLF) 15-binding
site was introduced into the p(-465)luc construct by a three-step
PCR mutagenesis with selected sense and antisense primers. The
sequences of all DNA constructs were confirmed by DNA sequencing.
2.4 Transfection and luciferase assay
BAEC or COS-7 cells were plated at a density of 1  105/well in a
six-well dish. After 24 h, transient transfections were performed
using Fugene 6 (Roche Molecular Biochemics) or Lipofectamine
2000 (Invitrogen) according to the instructions provided by the manu-
facturer. Cells were transfected using 2 mg of luciferase reporter
vector and 0.5 mg of the pCMV-b-galactosidase (pCMV-b-Gal). For
some experiments, expression plasmids for Sp/KLFs were
co-transfected at this time. After 24 h, luciferase activity and
b-galactosidase activity were measured. b-galactosidase activity was
used to normalize for transfection efficiency. Data are shown as
mean+ SD of triplicates of at least three independent experiments.
To overexpress Foxo3A, HUVECs were plated at a density of
1105 cells/well in a six-well dish and transfected with plasmids
coding for pcDNA3, Foxo3A-wt, and constitutive active FoxO3A-A3
using PromoFectin (Promocell). After 48 h, HUVECs RNA was pre-
pared and analysed by quantitative PCR (see Supplementary material
online, Figure S1).
2.5 Semi-quantitative PCR
Total RNA was isolated from HUVECs using the Total RNA Mini Kit
(Bio-Rad), and equal amounts were reverse-transcribed with iScript
cDNA Synthesis Kit (Bio-Rad). Following primers were used: BMPER
forward 50-AGGACAGTGCTGCCCCAAATG-30, BMPER reverse
50-TACTGACACGTCCCCTGAAAG-30, KLF15 forward 50-CTTCCA
GCCTACCCTGGAGGAG-30, KLF15 reverse 50-TTGGTGTACAT
CTTGCTGCAGCC-30. hRPII forward 50-GCACCACGTCCAAT
GACAT-30 and hRPII reverse 50-GTGCGGCTGCTTCCATAA-30
served as internal control. The PCR amplification cycles consisted of
an initial denaturation step at 948C for 5 min, 35 cycles of denaturation
at 948C for 30 s, annealing at 60–64.38C for 30 s, and extension for
30 s. After a final extension of 5 min at 728C, PCR products were ana-
lysed using an ethidium bromide-stained 2% agarose gel. Gel bands
were semi-quantified using the Quantity One 1D Analysis Software
Version 4.4 (Bio-Rad). All RT–PCR experiments were repeated at
least three times and representative results are shown.
2.6 Western blot
HUVECs were stimulated for 72 h with 100 nM endothelin-1 in endo-
thelial cell growth medium (Provitro) with 0.5% FBS. Cell lysates were
resolved on a reducing polyacrylamide gel, plotted onto a nitrocellu-
lose membrane (Amersham Bioscience), and blocked with 5%
non-fat dry milk powder in PBS/Tris with 0.1% Tween 20 for 2 h at
room temperature (20–228C). The membrane was then incubated
with primary antibody overnight at 48C. After 1 h of incubation with
the secondary antibody, proteins were visualized using ECL reagent
(Amersham). All western blots were repeated at least three times
and quantified data are shown.
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2.7 siRNA transfection
siRNA for human KLF15 and a non-specific control siRNA were pur-
chased from Invitrogen (KLF15siRNA1 sense: 50-GCAUUUCUGCUU
GCCCGAGUUUCCU-30 and KLF15siRNA2 sense: 50-UACCCU
GGAGGAGAUUGAAGAGUUU-30). HUVECs were plated 1 day
before transfection at a density of 4  104/well in a 12-well dish in
HUVEC medium with 10% FBS. HUVECs were transfected with
siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s protocol. Cells were harvested for RNA. Knockdown
efficiency was confirmed by RT–PCR. Gel bands were semi-quantified
using the Quantity One 1D Analysis Software Version 4.4 (Bio-Rad).
2.8 Electrophoretic mobility shift assay
Mouse yolk sac-derived embryonic endothelial cells (C166) were used
for binding analysis of endogenous KLF15 to the BMPER promoter as
they express significant amounts of KLF15. For supershift (SS) analysis,
KLF15-FLAG was overexpressed in COS7 cells. After 48 h, nuclear
extracts were prepared with a nuclear extraction kit (Active Motif,
Rixensart, Belgium). Gelshift analysis was performed with a 32P-labelled
BMPER oligonucleotide (sequence: 50-CGCTCAGCCACCCCTCCT
CCCG-30) containing the 50- CACCC-30 KLF-binding motif. The
kinase reaction consists of 37 mL purified water, 1 mL BMPER oligonu-
cleotide (25 ng/mL), 5 mL 10 kinase buffer, 5 mL of g-32P desoxyade-
nosine triphosphate (Amersham), and 1.5 mL of T4 kinase and was
incubated for 30 min at 378C. The protein content of nuclear extracts
was determined using the Bradford Assay (Bio-Rad). Equal amounts of
protein were added to the labelled oligonucleotide. Afterwards, 18 mL
of reaction mixture, containing 22.5 mM Hepes–KOH, pH 7.9, 2.6 mM
MgCl2, 13.3% glycerol, 50 mM KCL, 0.125 mM EDTA, 0.5 mM dithio-
threitol, 0.5 mg/mL poly(dI-dC), and subsequently 0.5 ng of
32P-labelled oligonucleotide, was added. The samples were incubated
for 20 min at room temperature and then loaded on a 4% non-
denaturating polyacrylamide gel running in 0.5  Tris-borate-EDTA
buffer. Gels were vacuum-dried for 40 min on a 3 mm chromatography
filter (Whatman) and exposed to a radiograph film (Kodak
Biomax MR).
2.9 Statistical analysis and quantification
Statistical analyses were performed using GraphPad Prism 4.0. Data are
presented as mean+ SD, and comparisons were calculated by Stu-
dent’s t-test (two-sided, unpaired). Results were considered statisti-
cally significant when P , 0.05. Densitometric analysis of western
blots and RT–PCR was performed using Quantity One 1-D Analysis
Software Version 4.4 (Bio-Rad), and levels of significance were
calculated by one-sample t-test.
3. Results
3.1 Characterization of the BMPER
promoter
To study BMPER regulation, we dissected the murine BMPER pro-
moter and searched for transcription factors which regulate
BMPER promoter activity. Comparison of the 2000 base pairs
upstream of the translational start site between human and
mouse revealed four regions of particularly high degree of hom-
ology (R1–R4, Figure 1A). To characterize the role of these
highly conserved regions, we generated deletion constructs of
the BMPER promoter to drive luciferase as a reporter using the
boundaries of these regions as deletion sites: p(-1853)luc,
p(-1370)luc, p(-465)luc, p(-297)luc, and p(-97)luc. The BMPER
Figure 1 The conserved domains of the 50 flanking region of the BMPER gene contain positive and negative acting cis-elements. (A) Com-
parison of the human and mouse 50 flanking region of the BMPER gene using mVISTA reveals four highly conserved regions (R1–R4) from
22000 bp to the translational start site. (B) Deletion analysis of the BMPER promoter in BAECs. Cells were transfected with the respective
promoter construct, and luciferase activity was quantified. Values represent the mean+ SD of three independent experiments normalized
to b-galactosidase (*P , 0.05 vs. pGL3-basic; #P , 0.05 vs. p(2465)luc).
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promoter fragments were transfected into BAECs, and their
transcriptional activity was measured (Figure 1B). Deletion of the
promoter fragments from 21853 to 21370 bp as well as from
21370 to 2465 bp resulted in an increase in promoter activity.
This suggests that negative regulatory cis-elements are located
within these regions (Figure 1B). In contrast, deletion of the prox-
imal promoter led to a reduction of the promoter activity by 86%,
pointing to activating cis-elements contained in the proximal pro-
moter. In silico analysis indicated that the region from 2297 to
1 bp contains two domains that are highly conserved between
mouse and human (.75%). Furthermore, this promoter region
is guanin- and cytosin-rich (74.5%) and contains predicted
binding sites for members of the Sp1 and the KLF family of tran-
scription factors (Figure 2A).
3.2 KLF15 regulates BMPER expression
On the basis of in silico prediction, we hypothesized that members
of the Sp/KLF family of transcription factors may bind to the
BMPER promoter and regulate BMPER expression (Figure 2A).
Searching for a member of the Sp/KLF family with the ability to
regulate the proximal BMPER promoter, we tested Sp1, Sp3,
KLF2, KLF4, and KLF15 (Figure 2B). When the respective
expression plasmids were transfected along with p(-297)luc, the
strongest promoter induction was obtained by KLF15,
followed by KLF2 and KLF4. Sp1 and Sp3 did not activate
the BMPER promoter, and they even behaved as inhibitors
(Figure 2B).
3.3 Sp1 attenuates KLF15-induced
BMPER promoter activation
Next, we asked whether KLF15 interacts with Sp1 family members,
resulting in the modification of BMPER promoter regulation, as it
has been reported before for other promoters, such as
AceCS2.19 To test this notion, KLF15 was transfected together
with various amounts of Sp1, and the effect on promoter activity
was compared. We found that KLF15-induced promoter activity
is repressed by increasing amounts of Sp1, suggesting a functional
antagonism between KLF15 and SP1 (Figure 2C).
Along the same line of evidence, we found that the inhibition of
KLF15 using specific siRNA reduced BMPER expression in endo-
thelial cells as reflected by BMPER RNA (Figure 3A) and protein
levels (Figure 3B). Taken together, these data suggest that KLF15
is a key activator of BMPER expression.
3.4 KLF15 binds the KLF-motif in the
BMPER promoter
To narrow-down the region of KLF15 binding to the BMPER pro-
moter, we investigated the ability of KLF15 to transactivate differ-
ent promoter deletion fragments. Therefore, KLF15 was
overexpressed in the presence of the various BMPER promoter
reporter constructs, and luciferase activity was quantified
(Figure 4A). As expected from our previous experiments, KLF15
strongly upregulated the reporter constructs containing the pro-
moter fragments [p(-1370)luc (5.7-fold) and p(-297)luc
(5.2-fold)]. But, a significant loss of KLF15 reactivity was detected
Figure 2 Members of the SP/KLF family regulate BMPER expression. (A) Schematic representation of the Sp1- and KLF-binding sites within
the region 2297 to 1 bp of the translational start site of the BMPER gene as analysed by in silico prediction software (www.genomatix.de).
(B) Overexpression of KLF15 induces BMPER promoter activity in COS-7 cells. The p(2297)luc promoter construct was co-transfected
with pcDNA3 (empty vector) or the expression plasmids encoding for Sp1, Sp3, KLF2, KLF4, and KLF15, respectively. The results represent
the mean+ SD of three independent experiments (*P , 0.05 vs. pcDNA3). (C) Overexpression of Sp1 reverses KLF15- induced BMPER pro-
moter activity in a dose-dependent fashion. The promoter construct p(2297)luc was co-transfected with KLF15 and increasing amounts of Sp1.
The relative promoter activity was represented as the fold increase compared with the control (pcDNA3). The results represent the
mean+ SD of three independent experiments (*P , 0.05 vs. pcDNA3; #P , 0.05 vs. p(2297)lucþKLF15).
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between 2297 and 297 bp upstream of the translational start
site, suggesting the presence of a KLF15 response element in this
region. Next, we analysed this 200 bp DNA fragment in more
detail. A highly conserved KLF consensus-binding element
50-CACCC-30 was predicted by in silico analysis at 2284 bp.19,20
Comparison of this sequence derived from the BMPER promoter
with well-characterized KLF15 response elements from other pro-
moters such as the GLUT4 and the AceCS2 promoter revealed a
high degree of homology between the sequences (Figure 4B). To
determine the functional relevance of this motif in the BMPER pro-
moter, we inactivated the binding element by site-directed muta-
genesis. The KLF-mutated promoter construct p(KLF-mut)luc
showed only 45% promoter activity compared with the respective
wildtype construct (Figure 4C). This result indicates that the
2284 bp KLF-binding motif is essential for maximal promoter
activity.
As we have identified the KLF15 response element within the
BMPER promoter, we next set out to characterize the binding of
KLF15 to the BMPER promoter in gelshift assays. Nuclear extracts
of C166 cells, which express high levels of KLF15, were prepared
and used for gelshift analysis. Incubation of the nuclear extracts
with the radiolabelled AceCS2-oligonucleotide containing the
known KLF15-binding site (AceCS2-wt-P32) resulted in the
formation of three protein–DNA complexes (Figure 4D, lane 1).
As expected, the three complexes could be effectively competed
by the addition of excessive amounts of unlabelled AceCS2-wt oli-
gonucleotide (Figure 4D, lane 2) or unlabelled BMPER-wt oligonu-
cleotide (Figure 4D, lane 4). In contrast, competition with
unlabelled oligonucleotide containing a mutated KLF-binding
sequence (BMPER-KLF-mut, Figure 4D, lane 5) or a non-specific oli-
gonucleotide (Figure 4D, lane 3) did not affect the formation of the
protein–DNA complexes. These findings clearly demonstrate that
the DNA–protein complexes that are formed by the
KLF15-binding element within the AceCS2 promoter are formed
by the newly described KLF15-binding element in the BMPER pro-
moter. As expected, the mutated KLF15-binding element in the
BMPER promoter is not able to bind the respective proteins. To
prove direct binding of KLF15 to the BMPER promoter nuclear
extracts of COS7 cells overexpressing KLF15-FLAG (Figure 4E,
lanes 2–7) or pcDNA3 control (Figure 4E, lane 1) were incubated
with the radiolabelled oligonucleotide containing the KLF15
response element (BMPER-WT-P32). Comparison of nuclear
extracts from KLF15 overexpressing cells with control nuclear
extracts identified a KLF15-specific band (Figure 4E, lanes 1 and
2). As expected, the KLF15-derived complex could be effectively
competed by the addition of excessive amounts of unlabelled
Figure 3 Lack of KLF15 results in reduced BMPER RNA and protein expression in HUVECs. Specific silencing of KLF15 by siRNA in endo-
thelial cells resulted in decreased BMPER RNA (A) and protein (B) expression. (A) Two different siRNAs for KLF15 or control siRNA were
transfected in HUVECs. After 48 h, RNA was prepared and reverse-transcribed. RT–PCR was performed with specific primers for KLF15,
BMPER, and loading control hRPII. Panels to the right demonstrate the quantification of three independent experiments, one of which is
shown on the left (*P , 0.05 vs. control). (B) Lack of KLF15 results in reduced BMPER protein expression at 72 h post-transfection.
b-Tubulin served as the loading control. The right panel demonstrates the quantification of three independent experiments, one of which is
shown at the left (*P , 0.05 vs. control).
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Figure 4 (A–C) KLF15 binds to the positive-acting KLF motif in the BMPER promoter. (A) The inducibility of the BMPER promoter by KLF15
depends on the region from 2297 to 297 bp. Three deletion constructs of the BMPER promoter were co-transfected with KLF15 or pcDNA3
(empty vector). At 24 h after transfection, cells were harvested for luciferase assay. The results represent the mean+ SD of three independent exper-
iments (*P , 0.05 vs. pcDNA3). (B) Alignment of KLF motifs in the AceCS2 gene, the Glut4 gene along with the wildtype and the mutated motif in the
BMPER gene. (C) The KLF motif in the BMPER promoter at 2284 bp is essential for maximal transcriptional activity. The p(2465)luc and the mutated
p(KLF-mut)luc constructs were transiently transfected in COS-7 cells. At 24 h post-transfection, cells were harvested for luciferase assay. The results
represent the mean+ SD of three independent experiments. Mutation of the KLF15 motif in the BMPER promoter reduced promoter activity to 45%
of wildtype activity (*P , 0.05 vs. p(465)luc). (D and E) KLF15 binds specifically to the KLF motif in the BMPER promoter. (D) Nuclear extracts from
C166 cells were incubated with the 32P-labelled KLF15-binding-site-derived oligonucleotide from the AceCS2 promoter (lane 1). Cold competition
was performed using the same but unlabelled oligonucleotide (lane 2) or wildtype KLF15-binding-site-derived oligonucleotide from the BMPER pro-
moter (lane 4). Mutated KLF15-binding oligonucleotide from the BMPER promoter did not compete for DNA-protein complex formation (lane 3).
Incubation with an unrelated control oligonucleotide had no effect (lane 5). (E) Nuclear extracts from COS7 cells transfected with pcDNA3 (lane 1) or
the FLAG-tagged KLF15 expression vector were used in binding the 32P-labelled BMPER oligonucleotide (lane 2). Cold competition was performed
with an excess of unlabelled BMPER oligonucleotide BMPER-WT (lane 3). Incubation with mutated BMPER oligonucleotide BMPER-KLF-mut (lane 4)
orunrelated controloligonucleotide (lane 5)had noeffecton the formation of the three bands. SS studieswere performedusing an anti-FLAG antibody
(lane 6) or an unspecific IgG antibody as control (lane 7).
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BMPER-WT oligo (lane 3). In contrast, competition with unlabelled
oligonucleotide containing the KLF-mutated sequence
(BMPER-KLF-mut) did not affect the KLF15 complex (lane 4). Simi-
larly, the addition of unrelated non-specific oligonucleotide did not
affect the KLF15 complex (lane 5). Incubation with an anti-FLAG
antibody resulted in an SS of the KLF15 band, proving the speci-
ficity of this complex (lane 6). In contrast, the addition of a non-
specific antibody had no effect (lane 7). Taken together, these find-
ings demonstrate that KLF15 directly binds to the KLF-binding
motif that we have identified in the BMPER promoter.
3.5 Endothelin-1 downregulates BMPER
expression via the ETB receptor
in endothelial cells
To identify regulators of BMPER, we tested known mediators of
endothelial cell function and vascular homeostasis for their ability
to regulate BMPER expression in vitro. Endothelin-1 was a potent,
dose-dependent inhibitor of BMPER expression at the RNA and
protein levels (Figure 5A and B). Incubation of HUVECs with
endothelin-1 in the presence of the selective ETB endothelin
Figure 5 Endothelin-1 downregulates BMPER expression in endothelial cells. (A) Stimulation of HUVECs with the indicated concentrations of
endothelin-1 for 48 h. RNA was prepared and reverse-transcribed for RT–PCR using specific primers for hBMPER, hKLF15, and hRPII as a
control. One representative experiment out of three is shown. The panels to the right demonstrate the quantification of three independent
experiments. (B) BMPER protein expression is reduced in HUVECs after stimulation with 100 nM endothelin-1. After 72 h stimulation with
endothelin-1, cells were lysed, and western blot analysis for BMPER and b-tubulin (loading control) was performed. The right panel shows
the quantification of three independent experiments (*P , 0.05 vs. control). (C) Co-incubation of selective ETB endothelin-1 receptor antag-
onist BQ788 blocks downregulation of BMPER expression by endothelin-1. After 72 h stimulation with endothelin-1 alone or in combination
with BQ788 (2 mM), HUVECs were lysed and used for western blot analysis. GAPDH serves as loading control (*P , 0.05 vs. control).
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receptor antagonist BQ788 abolished the endothelin-1 effect,
suggesting that the ETB receptor transduces the downregulation
of BMPER by endothelin-1 (Figure 5C). Thus, we identified
endothelin-1 as the first cytokine shown to regulate BMPER and
demonstrated that the ETB receptor transduces this effect.
3.6 Endothelin-1 represses KLF15
expression in HUVECs
We hypothesized that endothelin-1-induced inhibition of BMPER
expression in endothelial cells may involve KLF15 because
endothelin-1 has been shown to inhibit KLF15 expression in cardi-
omyocytes.21,22 To confirm this hypothesis, we incubated HUVECs
with endothelin-1 and quantified KLF15 expression. Comparable
with what was reported in cardiomyocytes, we found a decrease
of KLF15 RNA levels upon endothelin-1 exposure in endothelial
cells (Figure 5A). Thus, KLF15 is a downstream target and a poten-
tial mediator of endothelin-1. Taken all our data together, this
suggests that KLF15 confers the effect of endothelin-1 on
BMPER expression.
4. Discussion
We present several novel findings with regard to the regulation of
BMPER in endothelial cells. First, within the BMPER promoter,
repressive elements are located at distance from the translational
start site, and activating elements are located in the proximal
section. Second, KLF15 is a potent activator of BMPER expression
and binds to a cis-acting KLF motif within the promoter (2284 bp)
that is necessary for maximal promoter activity. Third, KLF15 and
Sp1 functionally compete at the BMPER promoter. Fourth, we
demonstrate that BMPER is reduced by endothelin-1 via the ETB
receptor pathway. Fifth, endothelin-1 represses KLF15 in endo-
thelial cells, providing a potential mechanism for BMPER regulation.
BMPER is a key modulator in BMP signalling particularly in blood
vessel formation, and its expression is tightly regulated in a tem-
poral and spatial fashion.13 Thus, the regulation of BMPER
expression contributes to control BMP pathway activity. In the
present work, we set out to study the regulation of BMPER in
detail. In silico prediction revealed that the proximal promoter is
highly conserved (.75%, Figure 1A), GC-rich (74.5%), and contains
a binding site for KLF15 (Figure 2A). KLF15 is a member of the
family of Krüppel-like transcription factors. Out of this family,
so far KLF2, 4, and 6 have been implicated in physiological and
pathological vascular conditions.23– 26 Previous studies have
identified KLF15 as a negative regulator of cardiac hypertrophy
and fibrosis.21,27 Similar to BMPER, KLF15 is highly expressed in
vascular structures.20 The deletion of KLF15 in mice revealed a
vascular phenotype resulting from a thickened aortic media with
signs for augmented inflammatory gene expression and foci of
severe smooth muscle apoptosis, which further supports a role
for KLF15 and BMPER in vascular disease. Here, we characterize
KLF15 as an activator of endothelial BMPER expression
(Figures 2D and 3).
Vascular homeostasis is regulated by cytokines and growth
factors. Endothelin-1 is such a key vascular regulator. High concen-
trations of endothelin-1 cause oxidative stress and endothelial
dysfunction, including increased expression of vascular inflam-
mation markers (reviewed in 28). Moreover, endothelin-1 is
involved in the pathogenesis of pulmonary hypertension.29
Endothelin receptor antagonists such as bosentan are in clinical
use to lower pulmonary artery pressure. Interestingly, in cardio-
myocytes, endothelin-1 downregulates KLF15 and upregulates
BMP2, a BMP agonist that binds directly to BMPER.30
BMPs are involved in the lung and blood vessel formation. Loss
of function mutations of the BMP pathway result in pulmonary
hypertension.29 BMPER is a dose dependent regulator of BMP
activity and is involved in BMP-dependent vascular diseases.14
We have not yet investigated the effect of BMPER on pulmonary
artery hypertension, but the data obtained so far suggest that
BMPER may have an influence on this disease. First, BMPER is
strongly expressed in the lung,13 second, BMPER has activating
effects on endothelial cells,14 and third, BMPER-deficient mice
die from respiratory failure.31 In this paper, we link the
endothelin-1 pathway with the BMP pathway by the downregula-
tion of KLF15. Our data suggest a chain of events with KLF15 in
the central position to confer the effect of endothelin-1 on
BMPER expression.
Supporting in vivo evidence for the hypothesis that endothelin-1
and BMP signalling interact comes from the bone phenotypes in
gain and loss of function models. In rats, endothelin-1 promotes
bone formation, whereas the intake of an endothelin-1 receptor
antagonist results in osteopenia.32 Along the same line of evidence,
homozygous inactivation of endothelin-1 results in the impairment
of bone and cartilage development with reduced mandibles and
hypoplastic auricles.33 This phenotype is reminiscent to the bone
phenotype observed in BMPER2/2 mice.17,34
Taken together, we identify KLF15 as a direct transactivator of
BMPER. Since BMPER is a key regulator of BMP signalling, it is
crucial to understand how BMPER expression is regulated. In this
context, it is of great physiological relevance that endothelin-1
downregulates BMPER as well as its activator KLF15, suggesting
that KLF15 confers the endothelin-1 effect on BMPER expression.
Supplementary material
Supplementary Material is available at Cardiovascular Research
online.
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